Internal type bladder irrigation chemotherapy pump

Abstract

The invention discloses an internal type bladder irrigation chemotherapy pump, which comprises a chemotherapy pump elastic medicine storage bag, wherein an administration soft hose, which communicates with the chemotherapy pump elastic medicine storage bag, is arranged at one end of the chemotherapy pump elastic medicine storage bag; the end, away from the chemotherapy pump elastic medicine storage bag, of the administration soft hose is provided with an administration hard pipe which communicates with the administration soft hose; a clamp is arranged on the administration hard pipe; an administration pipe, which communicates with the chemotherapy pump elastic medicine storage bag, is arranged at the other end of the chemotherapy pump elastic medicine storage bag; and a valve is arranged on the administration pipe. According to the chemotherapy pump provided by the invention, medicines can be continuously applied to mucosa of a pathologically changed bladder wall through drop irrigation; the chemotherapy pump is fixed to the bladder mucosa by virtue of the clamp, and the medicines, which is applied through drop irrigation in a pipeline, can be siphoned and spread to surrounding bladder walls at the first time through the bladder mucosa, and finally the medicines can be siphoned and spread to the entire bladder wall; then, the medicines are mixed with urine, so that dilution of the medicines, before getting into contact with the bladder wall, is greatly relieved; an administration position is relatively precise; and the medicines, which are continuously discharged through drop irrigation, has a sufficient time to get into contact with the bladder wall, so that a recurrence rate of normuscle invasive bladder cancer which accepts transurethral resection of bladder tumor is reduced.

Description

technical field [0001] The invention mainly relates to the field of bladder perfusion chemotherapy, in particular to a built-in bladder perfusion chemotherapy pump. Background technique [0002] Non-muscle-invasive bladder cancer (Ta, T1, Tis) accounts for 70% of primary bladder tumors, of which Ta accounts for 70%, T1 accounts for 20%, and Tis accounts for 10%. According to the risk of recurrence and prognosis, non-muscle-invasive bladder cancer can be divided into three groups: low-risk, intermediate-risk, and high-risk. The main treatment for non-muscle-invasive bladder cancer is transurethral resection of bladder tumors. After resection of non-muscle-invasive bladder cancer, a considerable number of tumor recurrences are caused by residual tumors, especially for moderately and well-differentiated T1 tumors. For stage bladder cancer, according to literature reports, the residual tumor rate after the first resection can reach 33.8%-36%. Non-muscle-invasive bladder cancer...

AI Technical Summary

Problems solved by technology

[0003] 1. The solubility of chemotherapeutic drugs, with the continuous secretion of urine, the bladder volume increases, and gradually dilutes. After dilution, the drug concentration decreases, which will reduce the effect of chemotherapy. to the efficacy

[0004] 2. The drug is injected into the bladder through the urinary catheter at one time. The position of the drug attached to the bladder is not accurate, and the contact time with the diseased bladder wall is not sufficient. Adequate exposure to chemotherapy drugs leads to an increased recurrence rate after surgery

Images